|
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical research trials and An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome clinical trial. Test subjects typically obtain the finest healthcare available for their An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome  An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
For Condition: Acute Myeloid Leukemia,Myelodysplastic Syndrome
Status: Recruiting
Sponsor(s): Novartis Pharmaceuticals , Dana-Farber/Harvard Cancer Center,Memorial Sloan-Kettering Cancer Center,M.D. Anderson Cancer Center
Synopsis: Patients who agree to participate in this trial will be screened for the FLT 3 mutation. If positive they will have a physical exam, blood test, EKG, chest x-ray, bone marrow aspirate and a pregnancy test. Patients will be required to have weekly blood test and bone marrow aspirate monthly.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients: with AML who are not candidates for myelosuppressive chemotherapy or with AML who have relapsed disease or are refractory to standard therapy and not likely to require cytoreductive therapy within one month or with MDS subtypes RAEB, RAEB-T or CMML. - Who 0-2 - FLT 3 mutation - AML (MDS patients exempted) must have a total WBC (including blast) of > 5,000 - Patients must have a serum creatinine of < 1.5 x ULN, SGOT/SGPT < 3 x ULN and total bilirubin < 2.0 x ULN
Total Enrollment: 20
Location and Contact Information:
M.D. Anderson Cancer Center *Not yet recruiting*
Houston, Texas,
United States
Not yet recruiting Eli Estey 713-792-7544
Memorial Sloan Kettering Cancer Center *Recruiting*
New York City, New York,
United States
Recruiting Virginia Klimek 212-639-6519
Dana-Farber Cancer Institute *Recruiting*
Boston, Massachusetts,
United States
Recruiting Ilene Galinsky 617-632-3902
Additional Information:
Study ID Numbers: PKC4122104;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045942
Other Acute Myeloid Leukemia Studies:
1. Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
2. Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
3. Fluconazole Compared With Voriconazole in Preventing Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Transplantation
4. Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
5. Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Related Studies:
Other Acute Myeloid Leukemia Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
|
|
|
|
|
|
|
|
